Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
In anesthesia for ablation for cardiac arrhythmias, abrupt hemodynamic changes or fatal
arrhythmias can be seen frequently. Remimazolam is a novel ultra-short acting benzodiazepine
that provides good hemodynamic stability compared to conventional anesthetic agents. This
study aims to investigate whether remimazolam reduces vasoactive agent use during
cryo/radiofrequancy ablation under general anesthesia, compared to desflurane(RCT).